In an IBD cohort of 1004 patients previously treated with anti-TNF-α agents including infliximab, adalimumab, and certolizumab, psoriasis-like lesions were observed in 27 patients, mostly affected by CD [79]. The gene discussed is TNF; the disease is inflammatory bowel disease.